David A. Henderson, M.D., F.A.C.C.   OFFICE LOCATION Cardiology Research Associates (1999-Present) Cardiology Physicians, PA (1988-Present) 305 Memorial Medial Pkwy STE 301 Daytona Beach, Florida 32117   TELEPHONE: Office: 386-615-1521 Fax: 386-673-2787   Support Staff: Deborah Outler, R.N. Tyrone Bolden, M.A. Tracy Cromwell, M.A.

EDUCATION

 

MEDICAL LICENSE:

Florida (ME0038731)

 

 

CERTIFICATION

 

PROFESSIONAL SOCIETIES

 

Fellow- American College of Cardiology
American Medical Association
Volusia County Medical Society
Florida Medical Association
Heart Rhythm Society

 

 

HOSPITAL AFFILIATIONS

 

 

OFFICES HELD

 

ORIGINAL RESEARCH AND PUBLICATIONS

 

1) Henderson, D.A. and Bowyer, A.F.: Feasibility of Direct Coronary Blood Flow Measurements in Intact Human Subjects. West Virginia Medical Journal. September 1978 (abstract).

2) Henderson, D.A. (et.al.): Hospital Cost Containment: A Little Knowledge Helps. Abstract & Oral Presentation American Federation for Clinical Research. Spring Meeting April 1987. Washington.

3) Henderson, D.A. and Morgan, E.M.: Pneumomediastinum As a Complication of Athletic Competition. Thorax 36 (2): 155. 1981.

 

RESEARCH ACTIVITY

 

CONGESTIVE HEART FAILURE

Principal Investigator for Pfizer in trial of Effects of Eplerenone vs Placebo on CV mortality and HF hospitalization in patients with NYHA Class II Chronic systolic HF. (EMPHASIS)

Sub-Investigator for Scios in two clinical trials utilizing intravenous Natrecor in the treatment of decompensated congestive heart failure.

Sub-Investigator for SmithKline Beecham in a clinical trial for the treatment of stable NYHA Class II-III congestive heart failure. (ENCOR)

Sub-Investigator for Bristol-Myer Squibb in a clinical trial evaluating patients with chronic heart failure NYHA Class II-IV. (OVERTURE)

Sub-Investigator for Searle Pharmaceutical in a clinical trial for the treatment of heart failure following an acute myocardial infarction. (EPHESUS)

Principal Investigator for Centocor Phase II clinical trial for the treatment of heart failure Class III or IV evaluating the effects of Infliximab (Remicade) – (ATTACH)

Principal Investigator for St. Jude Medical in a heart failure Class III or IV ventricular resynchronization therapy randomized trial. (VECTOR)

Sub-Investigator for Myogen in an advanced heart failure Class III or IV placebo-controlled phase III clinical trial. (ESSENTIAL)

Sub-Investigator for Otsuka Maryland Research Institute Incorporated, Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure. (EVEREST)

 

LEFT VENTRICULAR DYSFUNCTION

Sub-Investigator for Norvartis in a clinical trial for treatment of high-risk patients after myocardial infarction. (VALIANT)

 

ACUTE MYOCARDIAL INFARCTION

Principal Investigator for Astra Zeneca in a randomized clinical trial (PLATO)A Study of PLATelet inhibition and Patient Outcomes.

Sub-Investigator for Centocor in a clinical trial for the treatment of acute myocardial infarction. (GUSTO V).

 

ACUTE CORONARY SYNDROME

Principal Investigator for Schering Plough in tiral to evaluate safety and efficacy of SCH530348 in addition to standard care in patients with ACS. (TRACER)

Principal Investigator for Schering Plough in trial of Benefit and Safety of Vytorin vs Simvastatin monotherapy in high risk subjects presenting with ACS. (IMPROVE-IT)

Principal Investigator for Roche Pharmaceuticals in a clinical trial for treatment of patients post acute coronary syndrome. (2nd SYMPHONY)

Sub-Investigator for Bristol Myers Squibb in a clinical trial for treatment of patients post acute coronary syndrome. (PROVE IT)

Sub-Investigator for Aventis open-label enoxaparin versus UFH in subjects who present to the emergency room with ACS. (RESCUE)

Sub-Investigator for AstraZeneca in a 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes. (LUNAR)

Principal Investigator for Eli Lilly in a Comparison of CS-747(Prasugrel) and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (TRITON)

 

ISCHEMIC/STABLE ANGINA

Principal Investigator for Momenta in trial to evaluate safety and efficacy of M118 in PCI in patients with stable CAD (EMMINENCE)

Principal Investigator for Schering Plough in trial to evaluate safety and efficacy of SCH530348 in addition to standard care in patients with atherosclerotic disease. (TIMI 50)

Sub-Investigator for Parke Davis in the treatment of patients with coronary artery disease, silent ischemia, and effort –induced angina. (QUASAR)

 

ARRHYTHMIAS

Principal investigator for Sanofi Aventis study to Assess Efficacy of Dronedarone for prevention of CV hospital izations or death from any cause in patients with AF /AFL. (ATHENA)

Principal Investigator for Sanofi Aventis toevaluate dronedarone vs amiodarone for maintenance of sinus rhythm in patients with AF (DIONYSOS)

Sub-Investigator for Knoll Pharmaceutical Company in the prevention of symptomatic recurrences of atrial fibrillation. (RAFT)

Principal Investigator for Proctor and Gamble, A Multi-Center, 12-Month Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 75 and 125 mg Doses of Oral Azimilide Dihydrochloride in Patients with an Implantable Cardioverter Defibrillator for the Treatment of Ventricular Arrhythmia. (SHIELD)

Principal Investigator for Proctor and Gamble, A Multi-Center, Open Label, Follow-Up Study to Assess the Long-Term Safety of 125 mg per day of Oral Azimilide Dihydrochloride in Patients with an Implantable Cardioverter Defibrillator. (SHIELD OPEN LABEL)

Principal Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for the treatment of atrial fibrillation in patients who require electrical cardioversion, with an open-label follow-up phase to assess the long-term efficacy and safety. (A-COMET I)

Principal Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for prophylactic treatment of atrial fibrillation and an open-label follow-up to assess the long-term efficacy and safety. (A-STAR)

Principal Investigator for Sanofi-Aventis in a Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (ATHENA)

 

ANTI-COAGULANT

Principal Investigator for Sanofi Aventis in a study of safety and efficacy of idraparinux in prevention of stroke and thrombotic events in patients with AF. (BOREALIS)

Principal Investigator for Aryx in a trial of ATI 5923 in comparison with warfarin (EMBRACE AC)

Sub investigator for Boehiner Ingleheim In a trial of dabigatran for prevention of stroke and septic embolism in patients with nonvalvular AF (RELY)

Sub-investigator for Astra Zeneca in a clinical trial to compare an oral direct thrombin inhibitor to dose-adjusted Coumadin in patients with atrial fibrillation. (SPORTIF V)

Sub-Investigator for Boehringer Ingelheim in a Randomized Evaluation of Long Term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etxilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RELY)

 

ANTI-PLATELET AGGREGATION

Principal Investigator for Astra Zeneca in a randomized clinical trial (PLATO)A Study of PLATelet inhibition and Patient Outcomes.

Sub-Investigator for Bristol-Myers Squibb and Sanofi-Snythelabo, Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. (ACTIVE)

 

HYPERLIPIDEMIA

Principal Investigator for Schering Plough in trial of Benefit and Safety of Vytorin vs Simvastatin monotherapy in high risk subjects presenting with ACS. (IMPROVE-IT)

Sub-Investigator for Pfizer in an open-label 8-week treatment clinical trial evaluating Atorvastatin doses in dyslipidemic patients. (AT GOAL)

Sub-Investigator for AstraZeneca in a placebo-controlled, phase III, clinical trial in the prevention of cardiovascular events among subjects with low levels of LDL-C and elevated levels of C-Reactive Protein (JUPITER)

 

CLAUDICATION

Sub-Investigator for Otsuka Pharmaceuticals in a clinical trial to assess the long-term effects of Pletal versus placebo for patients with intermittent claudication secondary to peripheral arterial disease. (CASTLE)

 

HYPERTENSION

Sub-investigator for Bristol Myers Squibb in a clinical trial of Omapatrilat versus Enalapril in mild-moderate/severe hypertension. (OCTAVE)

 

LEFT VENTRICULAR HYPERTROPHY

Principal Investigator for Norvartis in a multi-center, randomized, Double-Blind parallel group study to evaluate the efficacy of Lotrel and benazepril/hydrochlorothiazide in the regression of left ventricular hypertrophy by magnetic resonance imaging in patients with high risk hypertension. (ALIVE)

Sub-Investigator for GlaxoSmithKline in a randomized, double-blind, multi-center study comparing the effects of Carvedilol modified release formulation (COREG) and Atenolol in combination with and compared to an Angiotensin converting enzyme inhibitor (LISINOPRIL) on left ventricular hypertrophy. (CLEVER)

 

PCI STUDIES

Principal Investigator for Schering-Plough in a Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention (TRA)

 

METABOLIC SYNDROME STUDIES

Principal Investigator for Sanofi Aventis in a study of Rimonabant for reducing the risk of major CV events in abdominally obese patients with clustering of risk factors. (CRESCENDO)

 

PACEMAKER DEVICE TRIALS

Investigator for evaluation of St. Jude steroid active fixaton lead.

Investigator for St. Jude VDD pacing system.

Investigator for St. Jude AMPS trial: Atrial fibrillation and mode switching pacemaker study.

Principal Investigator for St. Jude in the TENDRIL FSR 1699T Lead Clinical Study 07/30/08

 

PUBLISHED ARTICLES

 

A Novel Lead Design Reduces Far Field R-Waves (FFRWs) and Decreases the Incidence of Inappropriate Automatic Mode Switch Episodes

 

 

 

 

Home | About Us | Office Locations | Procedures
Physicians | Prevention | Contact Us

 

 

The material provided on this site is for general information purposes only.
It is not intended to be used as medical advice and does not substitute
for proper consultation with trained medical personnel.